Hemo Organic Q1 Results FY27: Loss Narrows 13.42% to Rs 0.07 Crore as Revenue Falls to Nil
- July 16, 2026
- Posted by: Ankit Jaiswal
- Category: News
Hemo Organic Q1 FY27: revenue nil, down 100% from a small base a year ago. Net loss Rs 0.07 Cr, narrowed 13.42% from Rs 0.09 Cr. Gross loss narrowed 35.2%. Stock up 4.99% at Rs 24.42.
Hemo Organic Q1 results FY27 were announced on Wednesday, 15 July 2026, with the chemicals and rice trading company reporting nil revenue for the quarter ended 30 June 2026, down from a small base in the year ago quarter. The net loss in the Hemo Organic Q1 results FY27 narrowed 13.42% to Rs 0.07 crore from Rs 0.09 crore, while gross loss narrowed a sharper 35.2%.
Shares of Hemo Organic rose 4.99% to close at Rs 24.42, with the market responding positively to the narrower losses despite the revenue decline to nil for the quarter.
Click Here – Get Free Investment Predictions
Hemo Organic Q1 results FY27 Financial Highlights
The June quarter showed revenue falling to nil alongside narrowing losses at both the gross and net level, a combination central to the Hemo Organic Q1 results FY27. The table below summarises the numbers against the year ago quarter, in rounded crore terms.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 0.00 Cr | Rs 0.00 Cr | Unchanged, nil |
| Gross Profit / (Loss) | -Rs 0.07 Cr | -Rs 0.11 Cr | Loss narrowed 35.2% |
| Net Profit / (Loss) | -Rs 0.07 Cr | -Rs 0.09 Cr | Loss narrowed 13.42% |
With revenue at nil and losses narrowing at both the gross and net level in the Hemo Organic Q1 results FY27, the company appears to be managing its cost base more efficiently even without active revenue-generating operations this quarter.
Hemo Organic Q1 results FY27 Performance Analysis
Get Personalised Guidance from a SEBI-Registered Investment Advisor
The defining feature of the Hemo Organic Q1 results FY27 is the continued absence of reported revenue, consistent with the company’s history of minimal operating activity, though the narrowing losses at both the gross and net level suggest some improvement in cost management.
Hemo Organic has historically engaged in trading activities spanning chemicals, rice and textiles, along with plans for manufacturing specialty chemical intermediates, and the continued nil revenue suggests these various business lines have not generated billable activity this quarter.
The narrower loss in the Hemo Organic Q1 results FY27 despite nil revenue points to reduced operating costs during the quarter, though investors should note this reflects cost discipline rather than any return to active business operations.
Hemo Organic Q1 results FY27: Key Business Factors
1. Continued Absence of Revenue
The nil revenue, consistent with the company’s recent history, remains the central issue facing the company and raises questions about its current operational status.
2. Narrowing Losses Through Cost Management
Both gross and net losses narrowed this quarter, suggesting the company has taken steps to reduce operating costs even without active revenue-generating operations.
3. Diversified but Currently Inactive Business Lines
The company’s historical exposure to chemicals, rice trading and planned specialty chemical manufacturing offers potential future revenue avenues, though none appear active at present.
Dividend Details
No dividend was announced along with the June quarter numbers. With no reported revenue, dividend payments are not a realistic consideration for this company.
Hemo Organic Q1 results FY27 Outlook for the Full Year
Investors should watch for any signs of the company resuming active trading or manufacturing operations in coming quarters, particularly given its stated plans around specialty chemical intermediate production. Until revenue-generating activity resumes, the narrowing loss trend, while a modest positive, does not represent a return to a functioning core business.
Hemo Organic Stock Performance After the Q1 Results
Download the Univest iOS App or Univest Android App to track Hemo Organic live share price and upcoming quarterly results.
Hemo Organic share price rose 4.99% to close at Rs 24.42 after the Hemo Organic Q1 results FY27, with the market responding positively to the narrower losses reported.
As a micro cap stock with a history of minimal revenue-generating activity, the counter is likely to see limited trading liquidity, and investors should factor this into any position sizing decisions.
Key Risks
Investors going through the fine print of the Hemo Organic Q1 results FY27 should weigh the following risks with particular care.
1. No Reported Operating Revenue
The nil revenue in the Hemo Organic Q1 results FY27, consistent with recent quarters, is the most serious concern, raising questions about whether the company has any functioning core business at present.
2. Unclear Path to Revenue Resumption
Without concrete updates on the company’s planned specialty chemical manufacturing project or trading activities, investors have limited visibility into when, or if, revenue-generating operations might resume.
3. Micro Cap Liquidity and Governance Risk
As a micro cap stock with a history of minimal activity, investors should apply extra scrutiny to governance, disclosures and trading patterns before considering any position.
Conclusion
Hemo Organic Q1 results FY27 show continued nil revenue, with the net loss narrowing 13.42% to Rs 0.07 crore through apparent cost management rather than any return to active operations. The narrower loss offers a modest positive signal in the Hemo Organic Q1 results FY27, against the persistent absence of revenue and unclear path forward. Investors should treat this as an extremely high risk, speculative situation and consult a SEBI-registered advisor before considering any investment.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Hemo Organic Q1 results FY27
When were the Hemo Organic Q1 results FY27 announced?
Ans. The Hemo Organic Q1 results FY27 were announced on Wednesday, 15 July 2026, for the quarter ended 30 June 2026.
What was the revenue in Hemo Organic Q1 results FY27?
Ans. Revenue in the Hemo Organic Q1 results FY27 remained at nil, consistent with the company’s recent history of minimal operating activity.
Did Hemo Organic report a profit or loss in Q1 FY27?
Ans. The Hemo Organic Q1 results FY27 show a net loss of Rs 0.07 crore, narrowing 13.42% from a loss of Rs 0.09 crore in Q1 FY26, despite continued nil revenue.
What does Hemo Organic do as a company?
Ans. Hemo Organic has historically engaged in trading chemicals, rice and textiles, with stated plans to manufacture specialty chemical intermediates, though it has reported nil revenue in recent quarters.
How did Hemo Organic share price react to the Q1 results FY27?
Ans. Hemo Organic share price rose 4.99% to close at Rs 24.42 after the Hemo Organic Q1 results FY27.
Is Hemo Organic a good buy after the Q1 results FY27?
Ans. The Hemo Organic Q1 results FY27 show continued nil revenue despite a narrower loss, reflecting an extremely high risk, speculative situation. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.
